TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

分组1 - TG Therapeutics reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share, representing an earnings surprise of -46.88% [1] - The company posted revenues of $141.15 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.75%, compared to year-ago revenues of $73.47 million [2] - Over the last four quarters, TG Therapeutics has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] 分组2 - The stock has gained approximately 16.4% since the beginning of the year, outperforming the S&P 500's gain of 6.1% [3] - The current consensus EPS estimate for the coming quarter is $0.26 on revenues of $149.92 million, and $0.88 on revenues of $577.04 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]